Erasca Unveils First Clinical Candidates, Aims To Create A MAPK Clamp

SHP2, ERK Inhibitors Disclosed After Two Years, $300m In Funding

 
• By Mandy Jackson

Former Ignyta CEO’s well-funded Erasca obtained its first clinical-stage precision oncology candidates from NiKang and Asana, eyeing a first-in-class approach to RAS/MAPK-driven cancers.

staircase pathway in the beautiful forest
Erasca's first disclosed programs aim to shut down the RAS/MAPK pathway • Source: Shutterstock

More from R&D

More from Scrip